Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | Q9HBH1 | 1/20 | 0.32 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733066 | 1.00 | TSHR (0.33) | TSHRLMNACYP3A4NFKB1ADRA1A | |
| SCHEMBL1995258 | 0.86 | MMP1 (0.33) | TSHRLMNACYP3A4NFKB1ADRA1A | |
| SCHEMBL730936 | 0.86 | MMP1 (0.33) | TSHRLMNACYP3A4NFKB1ADRA1A | |
| SCHEMBL3513026 | 0.85 | TYR (0.37) | TSHRLMNACYP3A4NFKB1ADRA1A | |
| SCHEMBL8249267 | 0.84 | TSHR (0.33) | TSHRLMNACYP3A4NFKB1ADRA1A | |
| SCHEMBL731309 | 0.82 | PDF (0.34) | ||
| SCHEMBL1983553 | 0.82 | PDF (0.34) | ||
| SCHEMBL2049299 | 0.82 | CASP1 (0.39) | — | |
| SCHEMBL731986 | 0.82 | CASP1 (0.39) | — | |
| SCHEMBL6887447 | 0.81 | TSHR (0.34) | TSHRLMNACYP3A4NFKB1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637449-B2 | Processes for preparing protease inhibitors of hepatitis C virus | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637449-B2 | Processes for preparing protease inhibitors of hepatitis C virus | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8563505-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-22 | — | — | US | disclosed |
| EP-2331552-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2337784-B1 | MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20120232247-A1 | PROCESSES FOR PREPARING PROTEASE INHIBITORS OF HEPATITIS C VIRUS | MERCK SHARP & DOHME CORP. | 2012-09-13 | — | — | US | disclosed |
| US-20120232247-A1 | PROCESSES FOR PREPARING PROTEASE INHIBITORS OF HEPATITIS C VIRUS | MERCK SHARP & DOHME CORP. | 2012-09-13 | — | — | US | disclosed |
| EP-2331552-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-06-15 | — | — | EP | disclosed |
| WO-2011025849-A1 | PROCESSES FOR PREPARING PROTEASE INHIBITORS OF HEPATITIS C VIRUS | MERCK SHARP & DOHME CORP. (US) | 2011-03-03 | — | — | WO | disclosed |
| US-20100080771-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-01 | — | — | US | disclosed |
| WO-2010036551-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20100080770-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080771-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | TSHR 4631/4885LMNA 3735/4885CYP3A4 379/4885 |
| US-20100080770-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | TSHR 4631/4885LMNA 3735/4885CYP3A4 379/4885 |
| US-20120232247-A1 | PROCESSES FOR PREPARING PROTEASE INHIBITORS OF HEPATITIS C VIRUS | RNASE1, TMPRSS15, HAVCR2 | TSHR 4514/4885LMNA 1271/4885CYP3A4 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.